MEXICO.- Lung cancer is the most dangerous disease in Latin America. Lung cancer in Latin America is also one of the lowest attention to health care. "The Economist Intelligence Unit (EIU).
The study was conducted by the Mexican Society of Oncology (SMEO) and analyzed data from 12 Latin American countries. 99% of Mexico's lung cancer cases are in the third, and 85% of the other countries in the region.
IUMA Global Editorial Director Irene Mia pointed out that we do not have sufficient data or registrations in Latin America for identifying three priority areas in the health policies for cancer control. Tobacco use, early diagnosis.
Health experts who collaborate with researchers find that cancer of this type prevents high viruses and other resources that are linked to other cancers.
"Smoking patients are thought to have got this disease," said Dr. Nixon, head of the lug unit at the National Institute of Cancerology (UCAN). Oscar asked him. "He did enough to block the Mexican state of smoking."
Smokers are the leading cause of lung cancer, but it also provides 40% of water in arsenic, air pollution and firewood in the fuel cartridges.
In Mexico, this type of cancer does not include segurore population. 40% of the population does not have private insurance or social security, which helps keep the country low on the country. Tobacco control, access, early diagnosis.
In Latin America, 60,000 people die each year from lung cancer. In Mexico, 10,000 new cases were detected in 2010. By 2025 this would be reduced to 20,000. "Death rate is quite similar".
Reportedly, there is no single answer to the issues related to Latin America, and the research was conducted by the National Institute of Public Health. This study deals with the challenges for prevention, diagnosis and treatment of lung cancer. Latina
Pérez Quouzes said Mexico's authorities would get a proposal based on the costs to combat lung cancer and smoking in the Incan, Mexican Health Foundation and National Institute of Public Health in Mexico.
"Our expectation is that the respiratory cancer treatment policy is stable, the necessary background and the ability and the capability of treatment to be carried forward.